|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma显示文摘瞄准:为了评估免疫, interleukin-6 ( IL-6 )和从有肝细胞癌( HCC )和浆液的病人的肿瘤组织标本上的 IL-6 受体( IL-6R )的组织化学的本地化与 HCC 以及肝肝硬化( LC )在一组病人 IL-6 和 sIL-6R 铺平在一组有独自一个的 LC 并且在一个控制组的病人。方法:三组题目被学习:组我(n = 83 ) 受不了 HCC 和 LC,组 II (n = 72 ) 受不了独自一个的 LC 和组 III (n = 42 ) 同样健康的控制。所有病人有丙肝病毒感染。浆液 IL-6 和 IL-6R 层次用一个商业地可得到的 ELISA 工具包被决定。Immunohistochemistry 对 IL-6 和 IL-6R 用 streptavidin-biotin 建筑群和兔子 polyclonal 抗体被执行。结果:Immunohistochemistry 分析显示出媒介到强壮细胞质并且为 IL-6 和 IL-6R 的膜反应分别地在 HCC 的至少 40% 盒子,而肝肝硬化病人和控制为 IL-6 是否定的或为 IL-6R 显示出很温和、焦点的像点的细胞质的反应。在 HCC 组的浆液 IL-6 层次比在 LC 和控制组的那些显著地高(P <
0.0001 ) 。在在 3 个组之中的 sIL-6R 集中没有有效差量。当有 HCC 的病人根据 Okuda 的分类被划分成组时, IL-6 和 sIL-6R 水平的重要浆液增加从舞台被观察我上演 III (P <
0.02, P <
0.0005 ) 。当 HCC 和 LC 病人根据孩子呸被划分成肝硬化严厉的 3 个班时,在 HCC 病人的价值比在为各相应的班的 LC 病人的那些显著地高(P <
0.01 ).CONCLUSION:在 HCC 病人的 IL-6 浆液层次比在 LC 病人和控制的那些高,建议由肿瘤的房间的这 cytokine 的增加的生产。sIL-6R 价值在所有组是类似的,仅仅在阶段 III HCC 病人增加。这些数据建议他们与肿瘤的团而非与剩余的工作有一种更靠近的关系肝的质量。 | Soresi Maurizio Giannitrapani Lydia D'Antona Fabio Florena Ada Maria La Spada Emanuele Terranova Angela Cervello Melchiorre D'Alessandro Natale Montalto Giuseppe | 2006 | World Journal of Gastroenterology2006，12，16： | 25 |
| 2 | Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma显示文摘Interleukin-6 (IL-6) is a pleiotropic cytokine which is expressed in many inflammatory cells in response to different types of stimuli, regulating a number of biological processes. The IL-6 gene is polymorphic in both the 5' and 3' flanking regions and more than 150 single nucleotide polymorphisms have been identified so far. Genetic polymorphisms of IL-6 may affect the outcomes of several diseases, where the presence of high levels of circulating IL-6 have been correlated to the stage and/or the progression of the disease itself. The -174 G/C polymorphism is a frequent polymorphism, that is located in the upstream regulatory region of the IL-6 gene and affects IL-6 production. However, the data in the literature on the genetic association between the -174 G/C polymorphism and some specific liver diseases characterized by different etiologies are still controversial. In particular, most of the studies are quite unanimous in describing a correlation between the presence of the high-producer genotype and a worse evolution of the chronic liver disease. This is valid for patients with hepatitis C virus (HCV)-related chronic hepatitis and liver cirrhosis and hepatocellu-lar carcinoma (HCC) whatever the etiology. Studies in hepatitis B virus-related chronic liver diseases are not conclusive, while specific populations like non alcoholic fatty liver disease/non-alcoholic steatohepatitis, autoimmune and human immunodeficiency virus/HCV coinfected patients show a higher prevalence of the lowproducer genotype, probably due to the complexity of these clinical pictures. In this direction, a systematic revision of these data should shed more light on the role of this polymorphism in chronic liver diseases and HCC. | Lydia Giannitrapani Maurizio Soresi Daniele Balasus Anna Licata Giuseppe Montalto | 2013 | World Journal of Gastroenterology2013，19，16： | 19 |
| 3 | Non invasive tools for the diagnosis of liver cirrhosis显示文摘Liver cirrhosis(LC),the end stage of many forms of chronic hepatitis of different etiologies is a diffuse process characterized by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules surrounded by annular fibrosis.This chronic progressive clinical condition,leads to liver cell failure and portal hypertension,which can favour the onset of hepatocellular carcinoma.Defining the phase of the natural history is crucial for therapeutic choice and prognosis.Liver biopsy is currently considered the best available standard of reference but it has some limits,so alternative tools have been developed to substitute liver biopsy when assessing liver fibrosis.Serum markers offer a cost-effective alternative to liver biopsy being less invasive and theoretically without complications.They can be classified into direct and indirect markers which may be used alone or in combination to produce composite scores.Diagnostic imaging includes a number of instruments and techniques to estimate liver fibrosis and cirrhosis like ultrasound(US),US Doppler,contrast enhanced US andElastography.US could be used for the diagnosis of advanced LC while is not able to evaluate progression of fibrosis,in this case Elastography is more reliable.This review aims to revise the most recent data from the literature about non invasive methods useful in defining liver fibrosis. | Maurizio Soresi Lydia Giannitrapani Melchiorre Cervello Anna Licata Giuseppe Montalto | 2014 | World Journal of Gastroenterology2014，20，48： | 15 |
| 4 | Nanotechnology applications for the therapy of liver fibrosis显示文摘Chronic liver diseases represent a major global health problem both for their high prevalence worldwide and,in the more advanced stages,for the limited available curative treatment options.In fact,when lesions of different etiologies chronically affect the liver,triggering the fibrogenesis mechanisms,damage has already occurred and the progression of fibrosis will have a major clinical impact entailing severe complications,expensive treatments and death in end-stage liver disease.Despite significant advances in the understanding of the mechanisms of liver fibrinogenesis,the drugs used in liver fibrosis treatment still have a limited therapeutic effect.Many drugs showing potent antifibrotic activities in vitro often exhibit only minor effects in vivo because insufficient concentrations accumulate around the target cell and adverse effects result as other non-target cells are affected.Hepatic stellate cells play a critical role in liver fibrogenesis,thus they are the target cells of antifibrotic therapy.The application of nanoparticles has emerged as a rapidly evolving area for the safe delivery of various therapeutic agents(including drugs and nucleic acid)in the treatment of various pathologies,including liver disease.In this review,we give an overview of the various nanotechnology approaches used in the treatment of liver fibrosis. | Lydia Giannitrapani Maurizio Soresi Maria Luisa Bondì Giuseppe Montalto Melchiorre Cervello | 2014 | World Journal of Gastroenterology2014，20，23： | 9 |
| 5 | Magnetic resonance imaging of the cirrhotic liver in the eraof gadoxetic acid显示文摘Gadoxetic acid improves detection and characterization of focal liver lesions in cirrhotic patients and can estimate liver function in patients undergoing liver resection.The purpose of this article is to describe the optimal gadoxetic acid study protocol for the liver,the unique characteristics of gadoxetic acid,the differences between gadoxetic acid and extra-cellular gadolium chelates,and the differences in phases of enhancement between cirrhotic and normal liver using gadoxetic acid.We also discuss how to obtain and recognize an adequate hepatobiliary phase. | Francesco Agnello Marco Dioguardi Burgio Dario Picone Federica Vernuccio Giuseppe Cabibbo Lydia Giannitrapani Adele Taibbi Antonino Agrusa Tommaso Vincenzo Bartolotta Massimo Galia Roberto Lagalla Massimo Midiri Giuseppe Brancatelli | 2016 | World Journal of Gastroenterology2016，22，1： | 4 |
| 6 | Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results显示文摘 | Giuseppe Salvaggio Alessandro Furlan Francesco Agnello Giuseppe Cabibbo Daniele Marin Lydia Giannitrapani Chiara Genco Massimo Midiri Roberto Lagalla Giuseppe Brancatelli | 2014 | La radiologia medica2014，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员